Quarterly ResultMay 13, 2026, 05:27 PM
Capricor Therapeutics Q1 Net Loss Widens to $33.9M; EPS $(0.59)
AI Summary
Capricor Therapeutics reported a significant widening of its net loss to $33.9 million, or $(0.59) per share, for the first quarter of 2026, compared to a net loss of $24.4 million, or $(0.53) per share, in the same period last year. This was primarily driven by increased research and development expenses, which rose to $27.4 million, and higher general and administrative costs of $9.4 million. The company continued to report no revenue and experienced a substantial increase in net cash used in operating activities, reaching $29.3 million for the quarter.
Key Highlights
- Net loss widened to $33.9 million in Q1 2026 from $24.4 million in Q1 2025.
- Basic and diluted net loss per share was $(0.59) in Q1 2026, up from $(0.53) in Q1 2025.
- Research and development expenses increased to $27.4 million from $18.9 million year-over-year.
- General and administrative expenses rose to $9.4 million from $6.1 million year-over-year.
- Net cash used in operating activities was $29.3 million in Q1 2026, compared to $6.4 million in Q1 2025.
- Cash and cash equivalents decreased to $105.4 million as of March 31, 2026.
- Marketable securities increased to $173.2 million as of March 31, 2026.
- The company reported no revenue for both Q1 2026 and Q1 2025.
Price Impact
More from CAPR